Ribociclib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1228 publications

Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.

Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.

Journal: Future oncology (London, England)

Published: June 22, 2026

Hepatitis B Reactivation During Ribociclib Therapy in a Patient with Metastatic Breast Cancer.

Hepatitis B Reactivation During Ribociclib Therapy in a Patient with Metastatic Breast Cancer.

Journal: The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

Published: June 08, 2026

Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals.

Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals.

Journal: Cureus

Published: May 17, 2026

Vitiligo-Like Hypopigmentation Induced by Ribociclib in a Patient With Metastatic Breast Cancer.

Vitiligo-Like Hypopigmentation Induced by Ribociclib in a Patient With Metastatic Breast Cancer.

Journal: Cureus

Published: May 17, 2026

Predictors of hepatotoxicity in patients receiving CDK4/6 inhibitors: A real-world cohort study.

Predictors of hepatotoxicity in patients receiving CDK4/6 inhibitors: A real-world cohort study.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: May 14, 2026

Extensive Cutaneous and Scalp Metastases From Hormone Receptor-Positive Breast Cancer Successfully Treated With CDK4/6 Inhibitor Therapy: A Case Report.

Extensive Cutaneous and Scalp Metastases From Hormone Receptor-Positive Breast Cancer Successfully Treated With CDK4/6 Inhibitor Therapy: A Case Report.

Journal: Cureus

Published: May 03, 2026

Prognostic Role of Uric Acid-to-Albumin Ratio in Patients with Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

Prognostic Role of Uric Acid-to-Albumin Ratio in Patients with Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

Journal: Journal of clinical medicine

Published: April 22, 2026

Drug-Induced Pneumonitis Secondary to Ribociclib in a Patient With Metastatic Breast Cancer.

Drug-Induced Pneumonitis Secondary to Ribociclib in a Patient With Metastatic Breast Cancer.

Journal: Cureus

Published: April 13, 2026

Analysis of the Frequency and Associated Factors of Skin Toxicity in Patients Receiving Ribociclib-Based Therapy for Metastatic Breast Cancer.

Analysis of the Frequency and Associated Factors of Skin Toxicity in Patients Receiving Ribociclib-Based Therapy for Metastatic Breast Cancer.

Journal: Cancers

Published: April 09, 2026

CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers.

CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers.

Journal: Frontiers in immunology

Published: April 02, 2026

Selective effects of cyclin dependent kinase inhibitors in gammaherpesvirus reactivation from latency.

Selective effects of cyclin dependent kinase inhibitors in gammaherpesvirus reactivation from latency.

Journal: bioRxiv : the preprint server for biology

Published: March 27, 2026

CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer.

CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer.

Journal: Cureus

Published: March 25, 2026

Showing 1-12 of 1,228

Last Updated: 06/30/2026